- Home
- EYE vs ANAB Comparison
EYE vs ANAB Comparison
Compare EYE & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYE
- ANAB
- Stock Information
- Founded
- EYE 1990
- ANAB 2005
- Country
- EYE United States
- ANAB United States
- Employees
- EYE N/A
- ANAB N/A
- Industry
- EYE Ophthalmic Goods
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- EYE Health Care
- ANAB Health Care
- Exchange
- EYE Nasdaq
- ANAB Nasdaq
- Market Cap
- EYE 900.5M
- ANAB 759.5M
- IPO Year
- EYE 2017
- ANAB 2017
- Fundamental
- Price
- EYE $11.67
- ANAB $20.55
- Analyst Decision
- EYE Hold
- ANAB Buy
- Analyst Count
- EYE 6
- ANAB 10
- Target Price
- EYE $14.00
- ANAB $36.38
- AVG Volume (30 Days)
- EYE 1.9M
- ANAB 1.0M
- Earning Date
- EYE 05-07-2025
- ANAB 05-08-2025
- Dividend Yield
- EYE N/A
- ANAB N/A
- EPS Growth
- EYE N/A
- ANAB N/A
- EPS
- EYE N/A
- ANAB N/A
- Revenue
- EYE $1,823,320,000.00
- ANAB $91,280,000.00
- Revenue This Year
- EYE $6.62
- ANAB N/A
- Revenue Next Year
- EYE $2.62
- ANAB $37.76
- P/E Ratio
- EYE N/A
- ANAB N/A
- Revenue Growth
- EYE 3.81
- ANAB 432.03
- 52 Week Low
- EYE $9.56
- ANAB $12.21
- 52 Week High
- EYE $19.49
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- EYE 46.31
- ANAB 65.12
- Support Level
- EYE $11.29
- ANAB $15.40
- Resistance Level
- EYE $12.00
- ANAB $19.82
- Average True Range (ATR)
- EYE 0.81
- ANAB 1.49
- MACD
- EYE -0.07
- ANAB 0.16
- Stochastic Oscillator
- EYE 45.86
- ANAB 96.26
About EYE National Vision Holdings Inc.
National Vision Holdings Inc is an optical retailer in the U.S. Its product portfolio includes eyeglasses and sunglasses, contact lenses, accessories, and other products. The company has two operating segments; Owned and Host segment includes company-owned brands America's Best and Eyeglass World, In America's Best stores, vision care services are provided by optometrists or by independent professional corporations and Host operating consist of Military and Fred Meyer which provide eye exams by independent optometrists, and the Legacy segment manages the operations of, and supplies inventory and lab processing services to Legacy retail Vision Centers. It earns a majority of its revenue from the Owned and Host segment.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).